All relevant data are within the paper and its Supporting Information files. Additional genetic files if required, are available from the dbGAP database (accession number phs000920.v1.p1).

Introduction {#sec005}
============

Asthma affects more than 25 million people in the United States including 9.3% of all US children, with \$56 billion in annual healthcare and indirect costs.\[[@pone.0157848.ref001]\] Studies have suggested a range of 47 to 95% heritability for asthma,\[[@pone.0157848.ref002]--[@pone.0157848.ref004]\] with multiple associated genetic variants.\[[@pone.0157848.ref005]\] However, the individual effects of these variants are small,\[[@pone.0157848.ref006],[@pone.0157848.ref007]\] leading to questions about whether these genetic influences are more relevant in the broader context of specific environmental exposures.\[[@pone.0157848.ref008]\] Among the early environmental exposures associated with asthma, viral respiratory infections are among the most important.\[[@pone.0157848.ref009],[@pone.0157848.ref010]\] While interaction between viral illness and genetic variants on asthma risk has been reported,\[[@pone.0157848.ref011]\] mechanisms remain unclear.

A gene-infection interaction promoting airway remodeling and lung function decline may be important both in asthma and generating severe asthma phenotypes. The plasmin and fibrinolytic pathway may be particularly relevant in airway remodeling and upper respiratory infection is associated with increased fibrinogenic activities in subjects with recurrent wheezing or asthma.\[[@pone.0157848.ref012],[@pone.0157848.ref013]\] Specifically, *plasminogen activator inhibitor-1* (*PAI-1*) promotes fibrosis,\[[@pone.0157848.ref014],[@pone.0157848.ref015]\] and blocking of this enzyme prevents extracellular matrix (ECM) deposition.\[[@pone.0157848.ref016],[@pone.0157848.ref017]\] URI increases airway *PAI-1* levels, with virus inducing *PAI-1* production in human airway epithelial cells.\[[@pone.0157848.ref012]\] *PAI-1* promoter site genetic variants are strongly associated not only with plasma *PAI-1* levels,\[[@pone.0157848.ref018]\] but also with increased risk of asthma, decreased forced expiratory volume in 1 second (FEV~1~), and airway hyperreactivity.\[[@pone.0157848.ref019]\] \[[@pone.0157848.ref020]\]

We utilized the Genes-environments and Admixture in Latino Americans (GALA II) study to test our hypothesis that a *PAI-1* polymorphism in combination with infection in early life may be associated with asthma, asthma severity, and worse lung function.

Materials and Methods {#sec006}
=====================

Recruitment {#sec007}
-----------

Latino children, adolescents, and young adults aged 8--21 years from five centers (Chicago, Illinois; Bronx, New York; Houston, Texas; San Francisco Bay Area, California; and Puerto Rico) were enrolled in the GALA II cohort study from 2006 to 2011 (n = 4157 children of whom 2022 had asthma and 2135 were healthy controls). We excluded subjects who had incomplete genetic or clinical data for relevant covariates (n = 286 asthmatics and 388 controls), yielding an analyzing sample size of 3483 subjects (1736 with asthma and 1747 without asthma). Further details are available on the online supporting information file.

PAI-1 genotyping for *rs2227631* {#sec008}
--------------------------------

Genome-wide genotyping was performed with the Axiom LAT1 array (World Array 4; Affymetrix, Santa Clara, Calif) as previously described.\[[@pone.0157848.ref021]\] The *A* allele of the promoter site SNP, *rs2227631*, for the PAI-1 gene is a gain of function mutation associated with higher plasma levels of *PAI-1*,\[[@pone.0157848.ref018]\] and is included in this chip. In initial exploratory analyses, we evaluated the individual effects of *AG* and *AA* genotypes in combination with infection on asthma risk. While there was a dose effect, numbers were not sufficiently large to separately analyze the *AA*-infection group (for example *AA*-RSV is only 0.9% (31/3446). The *AG* and *AA* groups were combined for the primary analysis. For completeness, a secondary analysis for the primary outcome of asthma is presented in the E-tables with genotype expressed as *GG*, *AG*, and *AA*.

Bronchiolitis / RSV {#sec009}
-------------------

Symptomatic bronchiolitis / RSV episodes requiring medical attention within the first 2 years of life was ascertained by the following question: "Was \<CHILD\> diagnosed with bronchiolitis or RSV before age 2 yrs."

Other lower respiratory illness {#sec010}
-------------------------------

Symptomatic lower respiratory tract illnesses (LRI) [requiring medical attention]{.ul} within the first 2 years of life was ascertained by the following question: "Was \<CHILD\> seen by a doctor for chest illness before age 2 yrs."

Subject exposure classification {#sec011}
-------------------------------

Subjects were divided into subgroups to identify the independent and joint effects of LRI requiring medical attention and *rs2227631* genotype as follows: *GG* without LRI (*GG*-No LRI), *AG/AA* without any history of LRI (*AG/AA* No LRI), GG with history of LRI (*GG*+LRI), and *AG/AA* with history of LRI (*AG/AA*+LRI). A similar grouping was carried out for genotype and symptomatic bronchiolitis / RSV, with "no RSV" indicating that there was no severe symptomatic RSV bronchiolitis requiring medical attention (i.e. no severe RSV).

Outcome measures {#sec012}
----------------

The primary outcome was report of physician diagnosed asthma. Secondary outcomes included asthma exacerbations and lung function. Spirometry was performed using a KoKo spirometer (nSpire Health, Longmont, CO) according to the guidelines of the American Thoracic Society/European Respiratory Society. Measures analyzed included percent predicted FEV1, FVC, and FEV1/FVC ratio (National Health and Nutrition Examination Survey III reference standards). Subjects with asthma were categorized for exacerbation status based on each the following criteria assessed over the previous 12 months: oral steroid use for 2 or more weeks, ≥ 2 emergency room (ER) visits, and ≥ 2 hospital admissions.

Replication cohort {#sec013}
------------------

The Study of African Americans, Asthma, Genes & Environments II (SAGE II) was used to replicate the associations found in the GALA II study and is described elsewhere.\[[@pone.0157848.ref022]\] Briefly, the SAGE II study is an ongoing clinic-based multicenter asthma case-control study, including African American subjects with asthma (n = 666) recruited from the San Francisco bay area, conducted in parallel to GALA II using identical protocols and questionnaires.

Statistical analysis {#sec014}
--------------------

For descriptive statistics, the study population was divided into asthma and control subjects, and χ^2^ tests and *t* tests performed to describe differences in terms of demographic and clinical characteristics. Analyses on the outcome of asthma diagnosis included all subjects. However, asthma exacerbations and lung function analyses were limited to subjects with asthma. Separate logistic regression analyses were performed to estimate the associations of asthma with the *PAI-1* genotype at the *rs2227631* locus, early-infection (RSV or LRI) history, and the joint effect of genotype and infection. Similar logistic regression analyses were carried out for the outcome of asthma exacerbations limited to subjects with asthma. Both analyses controlled for age, sex, ethnicity, ancestry, socioeconomic factors, environmental factors (history of farm animal exposure, received antibiotics during first year), family history of asthma, African and European genetic ancestry, and recruitment site. For the analysis of lung function (percent predicted values) within asthmatics we used a multivariate linear regression model, adjusting for age, sex, ethnicity, socioeconomic factors, environmental factors (history of smoke exposure), medication for asthma control, and recruitment site. Lung function analyses which included the SNP or SNP-infection analyses also controlled for ancestry. For the asthma analyses, separate models were also generated to test for the significance of interaction terms for infection and risk genotype, including terms for the main effects of genotype risk allele and infection history.

Replication of these analyses was carried out in the SAGE study using the same approach. All statistical analyses were performed using SPSS software (Version 22.0, Statistical Package for Social Science, Chicago, IL, USA). P values \< 0.05 were considered statistically significant.

This study was approved by the institutional review boards at each study center (IRB for USCF, IRB for Northwestern University, IRB for The Ann and Robert H. Lurie Children's Hospital of Chicago, IRB for IRB for Texas Children's Hospital Baylor College of Medicine, IRB for Veteran's Caribbean Health Care System, IRB for Centro Neumologica Pediatrica, IRB for Jacobi Medical Center, IRB for CUNY). Written informed consent was obtained from the parents or legal guardians of all children and adult participants, and written informed assent was obtained from all children aged 12--18 years.

Data used in the performance of this analysis is included with the paper in [S1 File](#pone.0157848.s001){ref-type="supplementary-material"}.

Results {#sec015}
=======

Baseline characteristics {#sec016}
------------------------

[Table 1](#pone.0157848.t001){ref-type="table"} presents the distribution of selected characteristics for the overall study sample divided by asthma status. The mean age of the study population was 13 years and majority of participants were Mexicans (36.5%) or Puerto Rican (42.6%). Compared to those without asthma, subjects with asthma were more likely to have had a symptomatic episode of RSV bronchiolitis or other symptomatic lower respiratory illness before age 2 years old (9.3% vs 0.9%; or 55.4% vs 10.1%, respectively), but there was no significant difference in PAI-1 genotype. Other differences by asthma status were minor in magnitude and are described in the online supplement.

10.1371/journal.pone.0157848.t001

###### Demographic and clinical characteristics of subjects.

![](pone.0157848.t001){#pone.0157848.t001g}

  Variable                                               Total (n = 3483)   Asthma (n = 1736)   Non-asthma (n = 1747)   *P* value
  ------------------------------------------------------ ------------------ ------------------- ----------------------- --------------------------------------------------
  Age, mean (SD), years                                  13.18 (3.49)       12.60 (3.32)        13.75 (3.56)            **0.000** [^a^](#t001fn002){ref-type="table-fn"}
  Male, No (%)                                           1735 (49.8)        961 (55.4)          774 (44.3)              **0.000** [^b^](#t001fn003){ref-type="table-fn"}
  BMI, mean (SD)                                         23.51 (6.66)       23.25 (6.56)        24.60 (6.93)            **0.000** [^a^](#t001fn002){ref-type="table-fn"}
  Ethnicity, No (%)                                                                                                     
      Mexican                                            1271 (36.5)        602 (34.7)          669 (38.3)              **0.027** [^b^](#t001fn003){ref-type="table-fn"}
      Puerto Rican                                       1485 (42.6)        735 (42.3)          750 (42.9)              0.724
      Other Latino                                       620 (17.8)         338 (19.5)          282 (16.1)              **0.010** [^b^](#t001fn003){ref-type="table-fn"}
      Mixed Latino                                       106 (3.0)          61 (3.5)            45 (2.6)                0.107
  Ancestry proportion, mean (SD)                                                                                        
      African                                            0.14 (0.13)        0.15 (0.13)         0.13 (0.12)             **0.000** [^a^](#t001fn002){ref-type="table-fn"}
      European                                           0.59 (3.81)        0.54 (0.19)         0.65 (5.37)             0.216
  Country born: USA, No (%)                              1703 (49.6)        732 (43.0)          971 (56.2)              **0.000** [^b^](#t001fn003){ref-type="table-fn"}
  Recruited center, No (%)                                                                                              
      IL                                                 639 (18.4)         310 (17.9)          329 (18.8)              0.492
      TX                                                 365 (10.5)         197 (11.4)          168 (9.6)               0.087
      NY                                                 545 (15.7)         290 (16.8)          255 (14.6)              0.078
      SF                                                 636 (18.3)         317 (18.3)          319 (18.3)              0.955
      PR                                                 1289 (37.1)        614 (35.5)          675 (38.7)              0.056
  Frequency of allergic sensitization                    1809 (52)          1076 (62)           733 (42)                
  Family history of Asthma, No (%)                                                                                      
      Mother                                             771 (22.8)         561 (33.1)          210 (12.4)              **0.000** [^b^](#t001fn003){ref-type="table-fn"}
      Father                                             463 (14.4)         334 (20.8)          129 (8.0)               **0.000** [^b^](#t001fn003){ref-type="table-fn"}
      Siblings                                           1343 (41.6)        866 (53.4)          477 (29.8)              **0.000** [^b^](#t001fn003){ref-type="table-fn"}
  Infection history before age 2 yrs, No (%)                                                                            
      RSV bronchiolitis                                  177 (5.1)          161 (9.3)           16 (0.9)                **0.000** [^b^](#t001fn003){ref-type="table-fn"}
      LRI                                                1126 (32.7)        952 (55.4)          174 (10.1)              **0.000** [^b^](#t001fn003){ref-type="table-fn"}
          Environments                                                                                                  
  Pet exposure during 1^st^ yr of life, No (%)                                                                          
      Cat                                                371 (10.8)         179 (10.4)          192 (11.1)              0.501
      Dog                                                1165 (33.8)        542 (31.4)          623 (36.1)              **0.003** [^b^](#t001fn003){ref-type="table-fn"}
      Farm animals                                       358 (10.4)         148 (8.6)           210 (12.1)              **0.001** [^b^](#t001fn003){ref-type="table-fn"}
  Smoke, No (%)                                                                                                         
      Mother smoke during pregnancy                      168 (4.9)          97 (5.6)            71 (4.1)                **0.039** [^b^](#t001fn003){ref-type="table-fn"}
      Adults smoke before age 2yrs                       784 (25.3)         437 (27.7)          347 (22.8)              **0.002** [^b^](#t001fn003){ref-type="table-fn"}
      Children ever tried smoking                        150 (4.3)          58 (3.3)            92 (5.3)                **0.005** [^b^](#t001fn003){ref-type="table-fn"}
      Children current smoking                           1 (0.1)            0 (0.0)             1 (0.2)                 0.450
  Received antibiotics during 1^st^ yr of life, No (%)   1288 (41.7)        774 (49.7)          514 (33.6)              **0.000** [^b^](#t001fn003){ref-type="table-fn"}
  Daycare, No (%)                                        812 (23.8)         443 (25.9)          369 (21.7)              **0.004** [^b^](#t001fn003){ref-type="table-fn"}
      Socioeconomic characteristics                                                                                     
  Mother education, No (%)                                                                                              
      \< High school                                     1356 (38.9)        656 (37.8)          700 (40.1)              0.168
      High school                                        913 (26.2)         471 (27.1)          442 (25.3)              0.219
      Some college                                       1214 (34.9)        609 (35.1)          605 (34.6)              0.781
  Income, No (%)                                                                                                        
      \< \$25,000                                        1227 (35.2)        623 (35.9)          604 (34.6)              0.417
      \$25--75,000                                       1195 (34.3)        634 (36.5)          561 (32.1)              **0.006** [^b^](#t001fn003){ref-type="table-fn"}
      \> \$75,000                                        1061 (30.5)        479 (27.6)          582 (33.3)              **0.000** [^b^](#t001fn003){ref-type="table-fn"}
  Insurance, No (%)                                      2195 (93.1)        1631 (95.2)         1564 (91.0)             **0.000** [^b^](#t001fn003){ref-type="table-fn"}
  rs2227631, No (%)                                                                                                     
      GG                                                 1405 (40.3)        676 (38.9)          729 (41.7)              0.093
      AG                                                 1583 (45.4)        801 (46.2)          782 (44.8)              0.414
      AA                                                 495 (14.3)         259 (14.9)          236 (13.5)              0.233
      AG+AA                                              2078 (59.7)        1060 (61.1)         1018 (58.3)             0.093
  Lung function, mean (SD)                                                                                              
      FEV~1~% predicted (pre-BD)                         92.45 (15.65)      91.03 (16.03)       98.65 (12.04)           **0.000** [^a^](#t001fn002){ref-type="table-fn"}
      FVC % predicted (pre-BD)                           96.03 (15.62)      95.55 (16.17)       98.14 (12.78)           **0.000** [^a^](#t001fn002){ref-type="table-fn"}
      FEV~1~/FVC ratio % predicted (pre-BD)              96.53 (8.86)       95.54 (9.00)        100.86 (6.70)           **0.000** [^a^](#t001fn002){ref-type="table-fn"}

BMI, body mass index; IL, Illinois; TX, Texas; NY, New York; SF, San Francisco; PR, Puerto Rico; RSV, respiratory syncytial virus; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BD, bronchodilator

^a^ *P* \< 0.05 from the *t* test for Asthma vs Non--Asthma.

^b^ *P* \< 0.05 from the χ2 test for Asthma vs Non--Asthma.

Risk of asthma {#sec017}
--------------

[Table 2](#pone.0157848.t002){ref-type="table"} presents 2 separate models evaluating the effect of genotype, and infection (tested separately). Firstly, the *PAI-1* SNP *rs2227631* itself does not increase the odds of developing asthma. Second, there was a significant increase in the likelihood of asthma in subjects with a history of early life infection such as RSV bronchiolitis and other LRI (OR 9.9, 95% CI 4.9--20.2; OR 9.1, 95% CI 7.2--11.5, respectively). If the presence of either RSV or LRI was tested in a similar model, the findings were unchanged (OR 10.1, 95% CI 8.2--12.4). In Figs [1](#pone.0157848.g001){ref-type="fig"} and [2](#pone.0157848.g002){ref-type="fig"}, we display the joint association of the *PAI-1* risk genotype and early life infection with the diagnosis of asthma. While there was an increase of asthma risk in GG-RSV group, there was an even more dramatic increase in the *AG/AA*+RSV group ([Fig 1](#pone.0157848.g001){ref-type="fig"}---OR 4.1, 95% CI 1.5--11.2; OR 17.7, 95% CI 6.3--50.2, respectively). Similar findings of lesser magnitude were noted in the *GG*+LRI group and *AG/AA*+LRI group when compared to *GG* no LRI group ([Fig 2](#pone.0157848.g002){ref-type="fig"}---OR 7.7, 95% CI 5.5--11.0; OR 11.7, 95% CI 8.8--16.4, respectively). In models testing the interaction terms for LRI-genotype and RSV-genotype (accounting for main effects), the LRI-genotype interaction term was significant at a level of P = 0.014 and the RSV-genotype approached significance at a level of p = 0.08. Furthermore, in a subgroup analysis limited to subjects who had RSV or LRI, there was a clear genotype effect for the risk allele (*AG/AA*+RSV OR 4.3, 95% CI 1.04--17.95; *AG/AA*+LRI OR 1.58, 95% CI 1.06--2.34) compared to those who had RSV or LRI with the wild type *GG* allele. Finally, we also carried out a sensitivity analysis (since RSV was by report) whereby we combined those with either RSV or LRI by these definitions and found that the magnitude of effect was similar for the AA/AG+ either LRI or RSV (OR 12.9, 95% CI 9.6--17.3). The interaction term for any lower respiratory infection and genotype (accounting for main effects) was significant at the P = 0.002 level.

![Joint association of bronchiolitis/ RSV and *PAI-1* risk genotype (*rs2227631*) with Asthma.\
RSV indicates subjects who were diagnosed with bronchiolitis or RSV before age 2 years old. Adjusted for age, sex, ethnicity, ancestry, socioeconomic factors, environmental factors (history of farm animal exposure and received antibiotics during first year), family history of asthma and recruitment site.](pone.0157848.g001){#pone.0157848.g001}

![Joint association of early life lower respiratory tract infection and *PAI-1* risk genotype (*rs2227631*) with Asthma.\
LRI indicates subjects who were diagnosed with a lower respiratory tract infection requiring medical attention before age 2 years old. Adjusted for age, sex, ethnicity, ancestry, socioeconomic factors, environmental factors (history of farm animal exposure and received antibiotics during first year), family history of asthma and recruitment site.](pone.0157848.g002){#pone.0157848.g002}

10.1371/journal.pone.0157848.t002

###### Adjusted effects of *rs2227631*, and infection on asthma.

![](pone.0157848.t002){#pone.0157848.t002g}

  Analyses                                       N      OR[^\*^](#t002fn002){ref-type="table-fn"} (95% CI)   *P* value[^†^](#t002fn003){ref-type="table-fn"}
  ---------------------------------------------- ------ ---------------------------------------------------- -------------------------------------------------
  **Genotype alone---*rs2227631***                                                                           
      *GG*                                       1405   Reference                                            
      *AG/AA*                                    2078   1.051 (0.878--1.259)                                 0.588
  **Infection history before age 2 yrs alone**                                                               
      RSV bronchiolitis                          177    **9.920 (4.881--20.159)**                            **0.000**
      LRI                                        1126   **9.110 (7.233--11.474)**                            **0.000**

OR, odds ratio; CI, confidence interval; RSV, respiratory syncytial virus

\*Adjusted for age, sex, ethnicity, ancestry, socioeconomic factors, environmental factors (history of farm animal exposure and received antibiotics during first year), family history of asthma and recruitment site.

^†^*P* values from multivariate regression analysis. Statistically significant *P* values are indicated in bold.

Asthma Exacerbations {#sec018}
--------------------

[Table 3](#pone.0157848.t003){ref-type="table"} presents 3 separate models (limited to subjects with asthma) evaluating the effect of genotype, infection, and then the joint effect of genotype and infection on asthma severity using three different parameters: steroid use ≥ 2 weeks, ER visit ≥ 2 times, and hospitalization ≥ 2 times all in the previous12 months. Considered the effect of genotype alone, the *AG/AA* genotype showed more than 2 times higher risk of hospitalization (P = 0.046, OR 2.2 95% CI 1.0--4.6). Similarly, subjects with a history of RSV bronchiolitis had significantly higher risk of having an ER visit ≥ 2 times in the previous 12 months (P = 0.001, OR 2.0 CI 95% 1.3--3.1). While findings were similar in direction for LRI, they failed to reach significance (P = 0.18, OR 1.2 95% CI 0.92--1.6, respectively). Finally, the *PAI-1* SNP and RSV jointly increased the risk of ED visits and the risk of hospitalization by 1.8 and 3.1-fold respectively. However, there was no joint effect between the *PAI-1* SNP and LRI on these asthma severity parameters.

10.1371/journal.pone.0157848.t003

###### Adjusted effect of *rs2227631*, infection and *rs2227631* gene-infection interaction on asthma exacerbations.

![](pone.0157848.t003){#pone.0157848.t003g}

  Analyses                                       Steroid use ≥ 2 weeks in past 12months   ER visit ≥ 2 times in past 12months   Hospitalizations ≥ 2 timesin past 12months                                                      
  ---------------------------------------------- ---------------------------------------- ------------------------------------- -------------------------------------------- ----------- -------------------------------------- -----------
  **Genotype alone---*rs2227631***                                                                                                                                                                                              
      *GG*                                       Reference                                Reference                             Reference                                                                                       
      *AG/AA*                                    1.078 (0.774--1.501)                     0.66                                  0.931 (0.713--1.216)                         0.60        **2.152 (1.013--4.572)**               **0.046**
  **Infection history before age 2 yrs alone**                                                                                                                                                                                  
      RSV bronchiolitis                          1.243 (0.800--1.931)                     0.33                                  **2.004 (1.314--3.057)**                     **0.001**   1.589 (0.740--3.412)                   0.23
      LRI                                        1.262 (0.910--1.752)                     0.16                                  1.197 (0.917--1.562)                         0.18        1.285 (0.670--2.464)                   0.48
  **Gene-Infection analyses**                                                                                                                                                                                                   
    ***rs2227631-RSV***                                                                                                                                                                                                         
      *GG* No RSV                                Reference                                Reference                             Reference                                                                                       
      *AG/AA* No RSV                             1.089 (0.765--1.550)                     0.63                                  0.911 (0.689--1.204)                         0.51        1.728 (0.794--3.761)                   0.17
      *GG*+RSV                                   1.255 (0.529--2.977)                     0.61                                  **2.408 (1.053--5.506)**                     **0.04**    [‡](#t003fn004){ref-type="table-fn"}   0.99
      *AG/AA*+RSV                                1.274 (0.734--2.211)                     0.39                                  **1.854 (1.111--3.092)**                     **0.02**    **3.107 (1.143--8.450)**               **0.03**
    ***rs2227631- LRI***                                                                                                                                                                                                        
      *GG* No LRI                                Reference                                Reference                             Reference                                                                                       
      *AG/AA* No LRI                             0.954 (0.547--1.664)                     0.87                                  0.709 (0.469--1.069)                         0.10        2.075 (0.566--7.602)                   0.27
      *GG*+LRI                                   1.115 (0.634--1.961)                     0.71                                  0.859 (0.561--1.315)                         0.49        1.195 (0.278--4.970)                   0.80
      *AG/AA*+ LRI                               1.278 (0.758--2.155)                     0.36                                  0.991 (0.668--1.472)                         0.96        2.645 (0.750--9.334)                   0.13

OR, odds ratio; CI, confidence interval; RSV, respiratory syncytial virus

\*Adjusted for age, sex, ethnicity, socioeconomic factors, environmental factors (history of smoke exposure), medication for asthma control and recruitment site. Analyses of SNP and SNP-infection also controlled for ancestry.

^†^*P* values from multivariate regression analysis. Statistically significant *P* values are indicated in bold.

‡ unable to estimate stable odds ratio due to small cell size.

Lung function {#sec019}
-------------

[Table 4](#pone.0157848.t004){ref-type="table"} presents 3 separate models (limited to subjects with asthma) evaluating the effect of genotype, infection, and then the joint effect of genotype and infection on lung function including three parameters; FEV~1~% predicted, FVC % predicted, and FEV~1~/FVC % predicted. Only the FEV~1~/FVC ratio was reduced in AG/AA genotype compared to GG genotype. Early life history of LRI was associated with decreases in FEV~1~/FVC ratio; but this was not significant for RSV bronchiolitis. When we looked at the joint effect of PAI-1 genotype-and early life infections, FEV~1~% predicted, and FEV~1~/FVC % predicted were further reduced in *AG/AA*+LRI group compared to *GG* no LRI group (P = 0.03, coefficient β -2.06 95% CI -3.97---0.16; and P = 0.001, coefficient β -1.97 95% CI -3.10---0.84, respectively). Similar findings were noted in the analyses of RSV with lower FEV~1~% predicted in AG/AA-RSV group. The findings for FEV~1~/FVC % predicted neared significance but showed a similar magnitude and direction of findings.

10.1371/journal.pone.0157848.t004

###### Adjusted effect of *rs2227631*, infection and *rs2227631*gene-infection interaction on lung function in asthmatic subjects.

![](pone.0157848.t004){#pone.0157848.t004g}

  Analyses                                       FEV~1~% predicted              FVC % predicted   FEV~1~/FVC ratio % predicted                                         
  ---------------------------------------------- ------------------------------ ----------------- ------------------------------ ------ ------------------------------ -----------
  **Genotype alone---*rs2227631***                                                                                                                                     
      *GG*                                       Reference                                        Reference                             Reference                      
      *AG/AA*                                    -1.212 (-2.530--0.105)         0.07              -0.517 (-1.812--0.778)         0.43   **-0.787 (-1.570 ---0.003)**   **0.049**
  **Infection history before age 2 yrs alone**                                                                                                                         
      RSV bronchiolitis                          -1.854 (-4.315--0.606)         0.14              -1.032 (-3.458--1.393)         0.40   -0.988 (-2.430--0.453)         0.18
      LRI                                        -1.195 (-2.528--0.138)         0.08              -0.060 (-1.256--1.370)         0.93   **-1.311 (-2.090 ---0532)**    **0.001**
  **Gene-Infection analyses**                                                                                                                                          
    ***rs2227631-RSV***                                                                                                                                                
      *GG* No RSV                                Reference                      Reference         Reference                                                            
      *AG/AA* No RSV                             -1.051 (-2.414--0.312)         0.13              -0.299 (-1.639--1.041)         0.66   **-0.844 (-1.655 ---0.338)**   **0.04**
      *GG*+RSV                                   0.303 (-3.794--4.400)          0.88              1.005 (-3.024--5.033)          0.62   -0.848 (-3.285--1.589)         0.49
      *AG/AA*+RSV                                **-3.113 (-6.050 ---0.177)**   **0.04**          -1.741 (-4.628--1.146)         0.23   -1.601 (-3.347--0.146)         0.07
    ***rs2227631-LRI***                                                                                                                                                
      *GG* No LRI                                Reference                      Reference         Reference                                                            
      *AG/AA* No LRI                             -0.757 (-2.546--1.032)         0.41              -1.000 (-2.759--0.758)         0.26   0.243 (-0.816--1.301)          0.65
      *GG*+LRI                                   -0.326 (-2.382--1.731)         0.75              -0.348 (-2.369--1.673)         0.74   -0.095 (-1.122--1.311)         0.88
      *AG/AA*+ LRI                               **-2.063 (-3.971 ---0.155)**   **0.03**          -0.234 (-2.109--1.641)         0.81   **-1.971 (-3.101 ---0.843)**   **0.001**

FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BD, bronchodilator; CI, confidence interval; RSV, respiratory syncytial virus

\*Adjusted for BMI, socioeconomic factors, medication for asthma control and recruitment site. Lung function parameters (% predicted values) were already adjusted with age, sex, and race. Additionally genotype and genotype-infection analyses were corrected for ancestry.

^†^*P* values from multivariate regression analysis. Statistically significant *P* values are indicated in bold.

Replication {#sec020}
-----------

We evaluated the asthma associations in the SAGE cohort with similar results. The SNP itself was not associated with asthma (OR 1.27, 95% CI 0.85--1.88), while both RSV (OR 14.3, 95% CI 1.71--119.53) and LRI (OR 22.1, 95% CI 11.8--41.4) were associated. We also replicated the joint effects for SNP-LRI association. While there was an increase of asthma risk in GG-LRI group, there was an even more dramatic increase in the *AG/AA*+LRI group (OR 20.4, 95% CI 8.9--46.9; OR 26.7, 95% CI 11.2--63.9, respectively). Despite a similar direction and magnitude of association, we were not able to replicate the SNP-RSV associations in the smaller SAGE cohort due to small numbers (n = 9) in this sub-group (OR 5.81, 95%CI 0.54--62.3 for *AA/AG*+RSV group). We also were not able to replicate the exacerbation and lung function associations in SAGE, possibly due to the smaller sample size.

Discussion {#sec021}
==========

This study examines the effect of a common polymorphism in the *PAI-1* gene and early life lower respiratory infections including RSV/bronchiolitis in patients with asthma. While the genotype itself was not associated with asthma risk, there was a significant interaction between early life infection and genotype on the outcome of asthma diagnosis. Asthma risk increased 17-fold when this genotype was present in individuals with symptomatic RSV / bronchiolitis infection and almost12-fold in those with other LRI in early life requiring medical attention. This finding was replicated in the SAGE II cohort for LRI, but not RSV potentially due to the small numbers of SAGE II subjects in the *AG/AA*+RSV group. Both LRI and RSV infection severe enough to require medical attention (10% and 1% of our control subjects respectively) and the genotype in question are common.\[[@pone.0157848.ref023],[@pone.0157848.ref024]\] The frequencies of *AG* and *AA* genotypes were 45.4% and 14.3%; with an overall *A* allele frequency of 37%.

The joint effect of early life lower respiratory tract infection and the gain of function *PAI-1* SNP is in keeping with other studies which suggest that the *PAI-1* pathway is important in airway response to virus, and that an exaggerated response may be detrimental. *PAI-1* plasma levels are increased in young children who had history of URI-induced repeated wheeze.\[[@pone.0157848.ref013]\] Human rhinovirus infection increases the production of *PAI-1* in primary airway epithelial cells from subjects with asthma, and during an URI in subjects with asthma, nasal lavage and sputum *PAI-1* levels increase.\[[@pone.0157848.ref012]\] These findings serve as *in vitro* and *in vivo* evidence of impact of respiratory viral infections on *PAI-1* production in asthma. In murine models, *PAI-1* deficiency protected against airway fibrosis, whereas *PAI-1* overexpression enhanced fibrotic changes.\[[@pone.0157848.ref014],[@pone.0157848.ref015]\] Blocking *PAI-1* using either siRNA for *PAI-1* or a *PAI-1* inhibitor reduced airway inflammation, tissue remodeling and airway hyperreactivity.\[[@pone.0157848.ref016],[@pone.0157848.ref017]\]

The *rs2227631* SNP itself had significant influence on the FEV~1~/FVC ratio within our asthmatic subjects, which is contrast to the findings that this SNP alone was not associated with asthma risk. We did not have sufficient lung function data for non-asthmatic subjects to determine whether there is an effect in normal subjects who would presumably have less airway inflammation and less remodeling potential. Furthermore, early childhood lower respiratory tract infection and the SNP had a joint effect on FEV~1~ and the FEV~1~/FVC ratio. These findings raise the question of whether the *rs2227631* SNP, in the context of viral insult, may cause increased production of airway *PAI-1* enough to affect lung development in infants and cause structural airway changes that lead to lower lung function in subjects with asthma.

This study has a number of limitations. While there was a dose effect for A alleles in our preliminary analyses, our numbers were not sufficiently large to analyze the AA-infection group separately for RSV bronchiolitis. *AG* and *AA* groups were combined for the primary analysis to provide more precise and stable estimates. Secondly, both the PAI-1 SNP *rs2227631* \[[@pone.0157848.ref018],[@pone.0157848.ref025]\] and the *4G/5G* polymorphism are promoter site polymorphisms \[[@pone.0157848.ref019],[@pone.0157848.ref020],[@pone.0157848.ref026]\] in strong linkage disequilibrium (D' = 0.97),\[[@pone.0157848.ref018]\] making it difficult to determine which is functional even if the *4G/5G* variant had been sequenced. However, others have used the *rs2227631* genotype as a proxy for the *4G/5G* locus, and found it to be the variant which was most highly associated with *PAI-1* levels on GWAS analysis, suggesting that this may be the more important locus.\[[@pone.0157848.ref027]\] Third, the exposures of RSV/ bronchiolitis and LRI were based on a self-report questionnaire designed to elucidate infections resulting in lower respiratory symptoms in a child under the age of 2 years. This is based on the fact that most childhood respiratory illness is indeed due to viral pathogens as has been shown by the Hartert group.\[[@pone.0157848.ref024]\] While, it is also possible that a recall bias would have resulted in only more severe illnesses were reported, this is in keeping with our focus. Severe enough illness to require a visit to the physician increase the relevance of inflammation and *PAI-1*. Even if some subjects with less severe illness were systematically included in the "no severe infection group", this would bias our analysis towards the null hypothesis, making our findings even more robust. Finally, it is also possible that asthmatic subjects may have greater recall of early wheezing illnesses which may increase the magnitude of the wheezing illness--asthma association. However, this effect should not bias the effect of genotype on asthma when studied within these symptomatic subjects as was evaluated in the subgroup analysis. This effect was clearly present, in contrast to the main analysis, which showed no genotype effect. Furthermore, other viruses may have caused symptomatic bronchiolitis and termed "RSV" by health care providers.\[[@pone.0157848.ref024]\] Over 70% of bronchiolitis is associated with RSV,\[[@pone.0157848.ref024]\] with most severe bronchiolitis associated with RSV or RSV/rhinovirus co-infection.\[[@pone.0157848.ref028]\] Thus, RSV is likely to be further enriched in this group beyond 70%. Regardless, our analyses were also consistent for LRI, a proof of the general principle. The importance of any early viral illness in the development of asthma in a susceptible host is underscored by a recent report that all viruses resulting in symptomatic illnesses in the first year of life (not just RV or RSV), increased the risk of asthma by age 7.\[[@pone.0157848.ref029]\]

Conclusion {#sec022}
==========

In conclusion, a genetic variant of *PAI-1* which increases *PAI-1* production, together with either early life lower respiratory infection, was associated with asthma diagnosis, asthma exacerbations, and asthma severity based on reduced FEV~1~/FVC ratio in our Latino population. The asthma associations for genotype-LRI were replicated in a smaller African American population. Further prospective studies are needed to replicate our RSV-genotype findings in other non-latino populations, and determine if *PAI-1* variants may serve as a biomarker of risk, which may provide impetus for clinical trials of primary prevention of asthma. In the interim, *PAI-1* genotype in combination with significant LRI, identifies individuals at increased risk of developing asthma. Studies are needed to determine whether interventions affecting airway responses at time of early life LRI in these at risk individuals will decrease the chances of developing asthma.
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###### GALAII supporting data.

This file includes data used to perform the primary analyses for this paper.
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Click here for additional data file.
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